Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis

Company Overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Key Stats

• Today's Range: $0.59 to $0.61
• 50-Day Range: $0.58 to $0.88
• 52-Week Range: $0.43 to $2.05
• Volume: 3.10 million shs
• Average Volume: 1.77 million shs
• Market Capitalization: $154.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.79
• Consensus Rating: Buy

Adaptimmune Therapeutics Stock Analysis - MarketRank™

Adaptimmune Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 722nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Adaptimmune Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Adaptimmune Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adaptimmune Therapeutics is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adaptimmune Therapeutics is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adaptimmune Therapeutics has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.63% of the outstanding shares of Adaptimmune Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Adaptimmune Therapeutics has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Adaptimmune Therapeutics has recently decreased by 2.75%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adaptimmune Therapeutics does not currently pay a dividend.

Dividend Growth

Adaptimmune Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.63% of the outstanding shares of Adaptimmune Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Adaptimmune Therapeutics has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Adaptimmune Therapeutics has recently decreased by 2.75%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.04

News Sentiment

Adaptimmune Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ADAP on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

MarketBeat Follows

1 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.44% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.

ADAP Stock Analysis - Frequently Asked Questions

How have ADAP shares performed this year?

Adaptimmune Therapeutics' stock was trading at $0.7930 at the start of the year. Since then, ADAP stock has decreased by 23.7% and is now trading at $0.6049.
View the best growth stocks for 2024 here.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) issued its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. The biotechnology company had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.20 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative trailing twelve-month return on equity of 74.15%.

When did Adaptimmune Therapeutics IPO?

Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' top institutional shareholders include Matrix Capital Management Company LP (14.73%), Baillie Gifford & Co. (6.56%), PFM Health Sciences LP (3.91%) and FMR LLC (0.68%). Insiders that own company stock include Gavin Wood, Garry E Menzel, Cintia Piccina, Adrian Rawcliffe, William C Bertrand Jr, John Lunger and Elliot Norry.
View institutional ownership trends.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADAP
• CUSIP: N/A
• CIK: 1621227
• Web: www.adaptimmune.com
• Phone: 441235430000
• Fax: 44-12-3543-0001
• Employees: 449
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.79
• High Stock Price Target: $3.50
• Low Stock Price Target: $1.50
• Potential Upside/Downside: +360.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-113,870,000.00
• Net Margins: -25.43%
• Pretax Margin: -24.73%
• Return on Equity: -74.15%
• Return on Assets: -15.09%

Debt

• Debt-to-Equity Ratio: 0.62
• Current Ratio: 3.85
• Quick Ratio: 3.82

Sales & Book Value

• Annual Sales: $175.04 million
• Price / Sales: 0.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 3.56

Miscellaneous

• Outstanding Shares: 255,883,000
• Free Float: 224,051,000
• Market Cap: $154.78 million
• Optionable: Optionable
• Beta: 2.18